REGENER-AR
Bringing Regenerative Medicine into the market: Allogeneic eASCs Phase IB/IIA clinical trial for treating Rheumatoid Arthritis
| Coordinatore | TiGENIX NV
Organization address
address: RESEARCHPARK HAASRODE 1724 ROMEINSE STRAAT 12/2 contact info |
| Nazionalità Coordinatore | Belgium [BE] |
| Totale costo | 7˙644˙045 € |
| EC contributo | 5˙925˙461 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2011-two-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-01-01 - 2014-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
TiGENIX NV
Organization address
address: RESEARCHPARK HAASRODE 1724 ROMEINSE STRAAT 12/2 contact info |
BE (LEUVEN) | coordinator | 1˙341˙960.00 |
| 2 |
TIGENIX SA
Organization address
address: CALLE MARCONI 1 contact info |
ES (TRES CANTONS) | participant | 1˙589˙000.00 |
| 3 |
SISTEMIC SCOTLAND LIMITED
Organization address
address: CENTRE FOR INTEGRATED DIAGNOSTIC contact info |
UK (GLASGOW) | participant | 596˙117.60 |
| 4 |
CENTRO DE INVESTIGACIONES ENERGETICAS, MEDIOAMBIENTALES Y TECNOLOGICAS-CIEMAT
Organization address
address: Avenida Complutense 22 contact info |
ES (MADRID) | participant | 445˙879.50 |
| 5 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 413˙100.00 |
| 6 |
FARMA-CROS IBERICA S.L.
Organization address
address: CASTILLA LA MANCHA. POLIGONO INDUSTRIAL CAMPORROSSO 7 contact info |
ES (ALBACETE) | participant | 377˙200.00 |
| 7 |
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Organization address
address: 's Gravendijkwal 230 contact info |
NL (ROTTERDAM) | participant | 316˙291.20 |
| 8 |
"ZABALA INNOVATION CONSULTING, S.A."
Organization address
address: Paseo Santxiki 3 bis contact info |
ES (Mutilva Alta (Navarra)) | participant | 308˙790.00 |
| 9 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Organization address
address: University Offices, Wellington Square contact info |
UK (OXFORD) | participant | 293˙043.20 |
| 10 |
MONDRAGON ASSEMBLY SOCIEDAD COOPERATIVA
Organization address
address: POLIGONO INDUSTRIAL BAINETXE 5A contact info |
ES (ARETXABALETA) | participant | 244˙080.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Treating Rheumatoid Arthritis (RA) is a crucial challenge for the health systems. RA is the most common inflammatory arthritis, affecting 0.5% to 1% of the general population worldwide with little variation of the prevalence among countries. The current pharmacological management of RA involves early intervention with synthetic disease modifying anti-rheumatic drugs (DMARDs) either singly or in combination. Despite all those treatments, RA remains as an unmet clinical need where several concerns about long term treatments based on biologics have been arisen (Bongartz, 2009) while there are still approximately 20-40% of rheumathoid arthritis patients that do not have an adequate response to anti-TNF (Vander CB, 2006). The preclinical data obtained by the REGENER-AR consortium in a RA efficacy model in mice using allogeneic eASCs by intravenous route, demonstrated that mesenchymal expanded adult stem cells (eASC) extracted from adipose tissue have a large potential for treating RA. REGENER-AR consortium has defined a clinical translational project which aim is to develop a broadly available and clinically applicable treatment for RA by exploiting the biology of living human eASCs. To do that, the consortium is developing an Advanced Therapy Medicinal Product (ATMP) based on allogeneic eASCs for the treatment of RA (product internal code, Cx611) and ready for starting the clinical research (IMPD and clinical protocol has been approved by the regulatory agencies in January 2011). To accomplish this goal, it will be necessary to test this product through a phase Ib/IIa clinical trial in order to define the safety and feasibility of the systemic administration of allogeneic eASCS in patients with RA, but it will be necessary as well to advance in the difficulties that prevent cell therapy to be considered as a largely available product in the market facing several issues related to the production scale-up, effectively clinical treatment and regulatory affairs compilance'
Introduzione (Teaser)
EU scientists are developing a new treatment for rheumatoid arthritis (RA) based on the intravenous administration of allogeneic mesenchymal stem cells (MSCs) from fat tissue. Initial results showed that MSC therapy lead to a promising clinical outcome in treated patients